TACSTD2 and lung carcinoma: Thus, TROP2-targeted antibody-drug conjugates (ADCs), which link cytotoxic drugs to TROP2-specific antibodies and have succeeded in treating these cancers, may offer potential for lung cancer treatment (21, 22, 24).